Threshold Pharmaceuticals Announces Results of Two New Preclinical Studies Evaluating Novel Combinations 

Threshold Pharmaceuticals Announces Results of Two New Preclinical Studies Evaluating Novel Combinations of TH-302 With Immunotherapy, Antiangiogenic Therapy, and Radiotherapy to Be Presented at AACR Annual Meeting 2014
Marketwired
Threshold Pharmaceuticals Logo
View Comments